Skip to Content
Merck
CN
All Photos(1)

Documents

Safety Information

F-017

Supelco

(±)-Flecainide solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C17H20F6N2O3
CAS Number:
Molecular Weight:
414.34
EC Number:
MDL number:
UNSPSC Code:
41116107
PubChem Substance ID:
NACRES:
NA.24

grade

certified reference material

Quality Level

form

liquid

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

concentration

1.0 mg/mL in methanol

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

application(s)

clinical testing

format

single component solution

storage temp.

−20°C

SMILES string

O=C(NCC1CCCCN1)C2=CC(OCC(F)(F)F)=CC=C2OCC(F)(F)F

InChI

1S/C17H20F6N2O3/c18-16(19,20)9-27-12-4-5-14(28-10-17(21,22)23)13(7-12)15(26)25-8-11-3-1-2-6-24-11/h4-5,7,11,24H,1-3,6,8-10H2,(H,25,26)

InChI key

DJBNUMBKLMJRSA-UHFFFAOYSA-N

Gene Information

human ... SCN5A(6331)

General description

Flecainide, marketed under trade names such as Almarytm, Apocard, Ecrinal®, and Flécaine, is a class Ic antiarrhythmic drug used to prevent and treat a variety of cardiac arrhythmias. This Certified Spiking Solution® is suitable for use as a starting material in the preparation of calibrators, controls, or linearity standards in flecainide therapeutic drug monitoring methods by LC/MS or LC that ensure patients remain within the drug′s narrow therapeutic range.

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Ecrinal is a registered trademark of Laboratoires Asepta Corporation Monaco
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

Signal Word

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Target Organs

Eyes,Central nervous system

WGK

WGK 2

Flash Point(F)

49.5 °F

Flash Point(C)

9.7 °C

Regulatory Information

危险化学品

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Antiarrhythmic drug treatment after cardioversion of atrial fibrillation.
Ajay Vallakati et al.
Lancet (London, England), 380(9852), 1467-1468 (2012-10-30)
Catecholaminergic polymorphic ventricular tachycardia.
Antoine Leenhardt et al.
Circulation. Arrhythmia and electrophysiology, 5(5), 1044-1052 (2012-10-02)
[CME ECG 40. Vertigo with ST elevation in V2. Brugada syndrome].
Ardan M Saguner et al.
Praxis, 102(5), 305-307 (2013-03-01)
Lovely Chhabra et al.
Indian heart journal, 64(4), 404-407 (2012-08-30)
Flecainide (a class 1c antiarrhythmic) produces a dose-dependent decrease in intracardiac conduction. Its well known common electrocardiographic effects are prolongation of PR and QT intervals and the QRS complex duration. We report a case of flecainide toxicity in an elderly
Kosuke Doki et al.
Pharmacogenetics and genomics, 22(11), 777-783 (2012-09-04)
To investigate the association between age-related decline in flecainide clearance and CYP2D6 genotype, we conducted a population pharmacokinetic analysis of flecainide using routine therapeutic drug monitoring data. Population pharmacokinetic analysis was performed on retrospective data from 163 genotyped patients treated

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service